Oriva Therapeutics, a women’s health company developing first-in-class and best-in-class approaches to treat chronic, prevalent conditions affecting women, announced today its incorporation, as well...
Read more
Ona Therapeutics is a pioneer in the development of first-in-class antibody-drug conjugates (ADCs) that leverage the molecular basis of advanced cancer. Through collaboration with academic and clinica...
Read more
The funding will be used to advance the clinical development of SpliceBio’s lead gene therapy candidate, SB-007 for Stargardt disease, including the ongoing interventional Phase 1/2 ASTRA study and ...
Read more
Proceeds from the Series C will be deployed to finalize clinical validation and expedite the regulatory approval process of deepull’s UllCORE diagnostic system, which received Breakthrough Device De...
Read more
he round was led by imec.xpand with new investors EIC Fund, Fond ICO Next Tech, CDTI-Innvierte and Avançsa. Existing investors Asabys Partners, Aliath Bioventures and Vsquared also participated, brin...
Read more
Augustine Therapeutics, a pioneering biotech company focused on novel treatments for neurodegenerative and cardiometabolic diseases, today announced that it has raised EUR 17 million (USD 18.5 million...
Read more
ALLOX, a techbio company developing a proprietary technology to design new drugs targeting allosteric sites within oncology and other diseases, announces its incorporation today, as well as the succes...
Read more
Nuage Therapeutics (“Nuage”) announces today the successful closing of a €12 million Seed financing to support the development of its lead program and validate its pioneering drug discovery plat...
Read more
SpliceBio, a biotechnology company exploiting protein splicing to develop next generation gene therapies, today announced the completion of an oversubscribed €50 million series A financing. The fina...
Read more
Nuage Therapeutics has announced the closing of a financing round by Sabadell Asabys, the investment vehicle managed by Asabys Partners. With this injection of capital, the spin-off will start its w...
Read more
Splice Bio, a gene therapy company based on technology developed in the Muir Lab at Princeton University, announced today that it has appointed JeanPhilippe Combal as Chairman of its Board of Director...
Read more
Splice Bio, a biotech company based on technology developed in the Muir Lab at Princeton University, announced today a new investment into the Company led by Ysios Capital and joined by Asabys Partner...
Read more
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
A paper published in Alzheimer’s & Dementia: The Journal of the Alzh...
